Review of Endosaccular Flow Disrupters for Wide-Neck Aneurysm Treatment.

Abstract

Endosaccular flow disruption has emerged as a transformative approach for treating wide-neck intracranial aneurysms, which are characterized by neck diameters exceeding 4 millimeters or dome-to-neck ratios below 2. This review examines the technical specifications and clinical outcomes of major endosaccular devices, including the Woven EndoBridge (WEB) device, the Artisse embolization device, the Medina embolization device, the neck bridging device for bifurcation aneurysms, the polycarbonate urethane membrane-assisted device, the Galaxy saccular endovascular aneurysm lattice, and the Contour Neurovascular System. Analysis of pivotal trials reveals varying degrees of efficacy and safety across platforms. The WEB device demonstrated complete occlusion rates of 51.7% to 56.1% at 1 year, with adequate occlusion reaching 84.6% in the WEB Intrasaccular Therapy Study trial and sustained improvement in 76.8% of cases at 5 years. The Artisse system showed initial promise but concerning declines in adequate occlusion from 66.7% at 6 months to 57.1% at 36 months. More recent innovations such as the Galaxy SEAL device achieved complete occlusion in 76.9% of cases in preliminary studies in 1 year. Thromboembolic complications occurred in 12.9% to 17.7% of cases across devices though procedure-related mortality remained below 2%. While the WEB device has established a robust safety and efficacy profile through long-term follow-up data, newer technologies demonstrate promising early results but require extended surveillance. Current challenges focus on optimizing device sizing, improving delivery systems, and enhancing material properties to maximize occlusion rates while minimizing complications. The evolution of these technologies continues to expand treatment options for complex aneurysms previously challenging to address through conventional endovascular or surgical approaches.